Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)

High Ki-67 is strongly associated with the risk of CNS relapse in patients with mantle cell lymphoma. Two-year incidence of CNS relapse in patients with Ki-67 ≥ 30 exceeds 25%. The incidence was not decreased by rituximab, high-dose cytarabine, high-dose methotrexate or consolidative ASCT. Developme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2015-05, Vol.26 (5), p.966-973
Hauptverfasser:	Chihara, D., Asano, N., Ohmachi, K., Nishikori, M., Okamoto, M., Sawa, M., Sakai, R., Okoshi, Y., Tsukamoto, N., Yakushijin, Y., Nakamura, S., Kinoshita, T., Ogura, M., Suzuki, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Central Nervous System Neoplasms - chemistry Central Nervous System Neoplasms - mortality Central Nervous System Neoplasms - pathology Central Nervous System Neoplasms - therapy CNS relapse Female Humans Incidence Japan - epidemiology Kaplan-Meier Estimate Ki-67 Ki-67 Antigen - analysis Lymphoma, Mantle-Cell - chemistry Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - pathology Lymphoma, Mantle-Cell - therapy Male mantle cell lymphoma Middle Aged Multivariate Analysis Predictive Value of Tests Recurrence Retrospective Studies Risk Assessment Risk Factors Time Factors Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!